J 2024

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

EL-ASHWAH, Shaimaa, Jon SALMANTON-GARCIA, Yavuz M BILGIN, Federico ITRI, Pavel ZAK et. al.

Basic information

Original name

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Authors

EL-ASHWAH, Shaimaa, Jon SALMANTON-GARCIA, Yavuz M BILGIN, Federico ITRI, Pavel ZAK, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Luisa VERGA, Ali S OMRANI, Maria Gomes da SILVA, Tomas SZOTKOWSKI, Monia MARCHETTI, Caterina BUQUICCHIO, Marcio NUCCI, Martin SCHOENLEIN, Francesca FARINA, Caroline BESSON, Lucia PREZIOSO, Summiya NIZAMUDDIN, Julio DAVILA-VALLS, Sonia MARTIN-PEREZ, Valentina BONUOMO, Van Doesum JAAP, Maria Chiara TISI, Francesco PASSAMONTI, Gustavo-Adolfo MENDEZ, Stef MEERS, Johan MAERTENS, Alberto LOPEZ-GARCIA, Andreas GLENTHOJ, Matteo BONNANI, Ikhwan RINALDI, Irati ORMAZABAL-VELEZ, Jorge LABRADOR, Austin KULASEKARARAJ, Ildefonso ESPIGADO, Fatih DEMIRKAN, De Jonge NICK, Graham P COLLINS, Maria CALBACHO, Ola BLENNOW, Murtadha AL-KHABORI, Tatjana ADZIC-VUKICEVIC, Elena ARELLANO, Bojana MISKOVIC, Milos MLADENOVIC, Anna NORDLANDER, Zdenek RACIL, Emanuele AMMATUNA, Raul CORDOBA, Ditte Stampe HERSBY, Stefanie GRAEFE, Ziad EMARAH, Michaela HANAKOVA, Maria Vittoria SACCHI, Marriyam IJAZ, Laman RAHIMLI, Nunes Rodrigues RAQUEL, Giovanni Paolo Maria ZAMBROTTA, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO

Edition

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2024, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.600 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1080/10428194.2023.2280886

UT WoS

001103157000001

Keywords in English

Chronic myeloid leukemia; tirosine kinase inhibitor; COVID-19; SARS-CoV-2; neoplasia; vaccines

Tags

14110212, rivok

Tags

International impact, Reviewed
Změněno: 2/2/2024 11:07, Mgr. Tereza Miškechová

Abstract

V originále

Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
Displayed: 18/10/2024 19:27